CLINICAL TRIAL / NCT06481904

Inclusion Criteria: TZIELD-Exposed Cohort - Patients in the US diagnosed with Stage 2 T1D who are planned to initiate TZIELD treatment according to the currently approved label or who have initiated TZIELD treatment within 6 months prior to enrollment: - Day 1: 65 mcg/m2 - Day 2: 125 mcg/m2 - Day 3: 250 mcg/m2 - Day 4: 500 mcg/m2 - Days 5 through 14: 1,030 mcg/m2 per day - Cumulative dose is approximately 11,240 mcg/m2 - Appropriate written informed consent/assent as applicable for the age of the patient TZIELD-Unexposed Cohort - Patients in the US diagnosed with Stage 2 T1D but who are not treated with TZIELD - Appropriate written informed consent/assent as applicable for the age of the patient Exclusion Criteria: - Patients who initiated TZIELD treatment more than 6 months prior to enrollment - Patients who had participated in a previous clinical trial for TZIELD - Patients in an ongoing clinical trial of an investigational product or who had ended participation within 6 months prior to study enrollment; patients participating in other observational studies may be enrolled